Advertisement


Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Jacob J. Adashek, DO, of the University of South Florida and Moffitt Cancer Center, discusses data on combining immunoregulatory inhibition and targeted gene therapy, which may offer patients better outcomes (Abstract 10).



Related Videos

Skin Cancer
Immunotherapy

John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy

John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpoint inhibitors may lead to inferior overall survival in patients with stage III or IV melanoma. The antibiotics were also linked to a higher incidence of severe immune-mediated colitis (Abstract 56).

Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy.

Skin Cancer
Breast Cancer
Lung Cancer

Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoadjuvant trials to treat melanoma, breast, and lung cancers.

Immunotherapy

Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer

Dario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what promotes inhibitory receptor expression, and what limits the persistence of antigen-specific T cells.

Pancreatic Cancer
Immunotherapy

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).

Advertisement

Advertisement



Advertisement